These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 39219856)
1. SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART). Maitland K; Hamaluba M; Obonyo N; Oguda E; Mogoka C; Williams TN; Chaponda M; Miti S; Kamavu LK; Jonathan Gwasupika J; Connon R; Gibb DM; Dondorp A; Day N; White N; Walker AS; George EC; Wellcome Open Res; 2023; 8():484. PubMed ID: 39219856 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malaria. Leitgeb AM; Charunwatthana P; Rueangveerayut R; Uthaisin C; Silamut K; Chotivanich K; Sila P; Moll K; Lee SJ; Lindgren M; Holmer E; Färnert A; Kiwuwa MS; Kristensen J; Herder C; Tarning J; Wahlgren M; Dondorp AM PLoS One; 2017; 12(12):e0188754. PubMed ID: 29244851 [TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
4. Effects of sevuparin on rosette formation and cytoadherence of Plasmodium falciparum infected erythrocytes. Saiwaew S; Sritabal J; Piaraksa N; Keayarsa S; Ruengweerayut R; Utaisin C; Sila P; Niramis R; Udomsangpetch R; Charunwatthana P; Pongponratn E; Pukrittayakamee S; Leitgeb AM; Wahlgren M; Lee SJ; Day NP; White NJ; Dondorp AM; Chotivanich K PLoS One; 2017; 12(3):e0172718. PubMed ID: 28249043 [TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia. Maude RJ; Silamut K; Plewes K; Charunwatthana P; Ho M; Abul Faiz M; Rahman R; Hossain MA; Hassan MU; Bin Yunus E; Hoque G; Islam F; Ghose A; Hanson J; Schlatter J; Lacey R; Eastaugh A; Tarning J; Lee SJ; White NJ; Chotivanich K; Day NP; Dondorp AM J Infect Dis; 2014 Jan; 209(1):120-9. PubMed ID: 23943850 [TBL] [Abstract][Full Text] [Related]
6. A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial). Maitland K; Obonyo N; Hamaluba M; Ogoda E; Mogaka C; Williams TN; Newton C; Kariuki SM; Gibb DM; Walker AS; Connon R; George EC Wellcome Open Res; 2024; 9():281. PubMed ID: 39184127 [TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867 [TBL] [Abstract][Full Text] [Related]
8. DON in pediatric cerebral malaria, a phase I/IIA dose-escalation safety study: study protocol for a clinical trial. Nampota-Nkomba N; Nyirenda OM; Mallewa J; Chimalizeni Y; Dzabala N; Fay MP; Gopalakrishnan M; Laurens MB; O'Brien NF; Miller LH; Pierce SK; Riggle BA; Postels DG Trials; 2024 Jan; 25(1):87. PubMed ID: 38279124 [TBL] [Abstract][Full Text] [Related]
9. Assessment of parasite clearance following treatment of severe malaria with intravenous artesunate in Ugandan children enrolled in a randomized controlled clinical trial. Byakika-Kibwika P; Nyakato P; Lamorde M; Kiragga AN Malar J; 2018 Oct; 17(1):400. PubMed ID: 30376860 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Sissoko MS; Healy SA; Katile A; Zaidi I; Hu Z; Kamate B; Samake Y; Sissoko K; Mwakingwe-Omari A; Lane J; Imeru A; Mohan R; Thera I; Guindo CO; Dolo A; Niare K; Koïta F; Niangaly A; Rausch KM; Zeguime A; Guindo MA; Bah A; Abebe Y; James ER; Manoj A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Doumbo O; Duffy PE Lancet Infect Dis; 2022 Mar; 22(3):377-389. PubMed ID: 34801112 [TBL] [Abstract][Full Text] [Related]
12. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. West African Network for Clinical Trials of Antimalarial Drugs (WANECAM) Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364 [TBL] [Abstract][Full Text] [Related]
13. Thrombin Cleavage of Plasmodium falciparum Erythrocyte Membrane Protein 1 Inhibits Cytoadherence. Gillrie MR; Renaux B; Russell-Goldman E; Avril M; Brazier AJ; Mihara K; Di Cera E; Milner DA; Hollenberg MD; Smith JD; Ho M mBio; 2016 Sep; 7(5):. PubMed ID: 27624125 [TBL] [Abstract][Full Text] [Related]
14. A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. Macintyre F; Adoke Y; Tiono AB; Duong TT; Mombo-Ngoma G; Bouyou-Akotet M; Tinto H; Bassat Q; Issifou S; Adamy M; Demarest H; Duparc S; Leroy D; Laurijssens BE; Biguenet S; Kibuuka A; Tshefu AK; Smith M; Foster C; Leipoldt I; Kremsner PG; Phuc BQ; Ouedraogo A; Ramharter M; BMC Med; 2017 Oct; 15(1):181. PubMed ID: 28988541 [TBL] [Abstract][Full Text] [Related]
16. Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Sirima SB; Ogutu B; Lusingu JPA; Mtoro A; Mrango Z; Ouedraogo A; Yaro JB; Onyango KO; Gesase S; Mnkande E; Ngocho JS; Ackermann I; Aubin F; Vanraes J; Strub N; Carn G Lancet Infect Dis; 2016 Oct; 16(10):1123-1133. PubMed ID: 27430374 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Diawara H; Healy SA; Mwakingwe-Omari A; Issiaka D; Diallo A; Traore S; Soumbounou IH; Gaoussou S; Zaidi I; Mahamar A; Attaher O; Fried M; Wylie BJ; Mohan R; Doan V; Doritchamou JYA; Dolo A; Morrison RD; Wang J; Hu Z; Rausch KM; Zeguime A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Dicko A; Duffy PE; Lancet Infect Dis; 2024 Dec; 24(12):1366-1382. PubMed ID: 39153490 [TBL] [Abstract][Full Text] [Related]
18. A comparative clinical trial of sequential treatments of severe malaria with artesunate suppository followed by mefloquine in Thailand. Looareesuwan S; Wilairatana P; Molunto W; Chalermrut K; Olliaro P; Andrial M Am J Trop Med Hyg; 1997 Sep; 57(3):348-53. PubMed ID: 9311648 [TBL] [Abstract][Full Text] [Related]